SGMT
Sagimet Biosciences Inc.NASDAQHealthcare$5.32-3.38%ClosedMarket Cap: $170.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.49
P/S
0.00
EV/EBITDA
-2.28
DCF Value
$1.05
FCF Yield
-27.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-40.8%
ROA
-43.8%
ROIC
-51.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-10.8M | $-9.6M | $-0.30 | — |
| FY 2025 | $0.00 | NaN% | $-56.9M | $-51.0M | $-1.58 | — |
| Q3 2025 | $0.00 | NaN% | $-14.3M | $-12.9M | $-0.40 | — |
| Q2 2025 | $0.00 | NaN% | $-11.9M | $-10.4M | $-0.32 | — |
| Q1 2025 | $0.00 | NaN% | $-19.9M | $-18.2M | $-0.56 | — |
| Q4 2024 | $0.00 | NaN% | $-18.2M | $-16.2M | $-0.50 | — |
| FY 2024 | $0.00 | NaN% | $-54.5M | $-45.6M | $-1.45 | — |
| Q3 2024 | $0.00 | NaN% | $-16.9M | $-14.6M | $-0.45 | — |
| Q2 2024 | $0.00 | NaN% | $-10.6M | $-8.1M | $-0.25 | — |
| Q1 2024 | $0.00 | NaN% | $-8.8M | $-6.6M | $-0.23 | — |
| Q4 2023 | $0.00 | NaN% | $-9.5M | $-8.2M | $-0.45 | — |
| FY 2023 | $2.0M | 100.0% | $-30.7M | $-27.9M | $-1.53 | — |